

1 **Original Article**

2 **Dietary Supplementation with *Zooshikella marina* Improves Growth Performance,**
3 **Haemato-immunological Parameters and Disease Resistance Against *Streptococcus***
4 ***agalactiae* in Nile Tilapia (*Oreochromis niloticus*)**

5
6 **Chalanda Kamnerddee^{1,2}, Sumesa Puangpee^{1,2}, Poosana Kaewkong^{1,2}, Nutt**
7 **Nuntapong^{1,2}, Sunee Wanlem³ and Naraid Suanyuk^{1,2*}**

8 ¹Kidchakan Supamattaya Aquatic Animal Health Research Center and Aquatic Science and
9 Innovative Management Division, Faculty of Natural Resources, Prince of Songkla
10 University, Hat Yai, Songkhla, 90110 Thailand

11 ²Discipline of Excellence in Sustainable Aquaculture, Prince of Songkla University, Hat
12 Yai, Songkhla, 90110 Thailand

13 ³Faculty of Veterinary Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110
14 Thailand

15 ***Corresponding author:** Asst. Prof. Dr. Naraid Suanyuk

- 16 • **Address:** Kidchakan Supamattaya Aquatic Animal Health Research Center and
17 Aquatic Science and Innovative Management Division, Faculty of Natural Resources,
18 Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand
- 19 • **E-Mail address:** naraid.s@psu.ac.th
- 20 • **Telephone number:** +66 74286193

21 Abstract

22 The efficacy of dietary supplementation with *Zooshikella marina* cells or extract on
23 growth performance, haemato-immunological parameters and resistance against
24 *Streptococcus agalactiae* infection in Nile tilapia (*Oreochromis niloticus*) were studied. In
25 trial I (growth performance experiment), the fish received dietary supplementation of *Z.*
26 *marina* cells at concentrations of 0.5, 1.0 and 1.5 g/kg in the feed, or extracts at concentrations
27 of 2.5, 5.0 and 7.5 mg/kg, for comparison to fish fed with a control diet for 4 weeks. At 2 and
28 4 weeks of receiving experimental diets, the Nile tilapia receiving *Z. marina* cells at a
29 concentration of 1.5 g/kg or extracts at 7.5 mg/kg showed significantly better final weight,
30 weight gain, specific growth rate and feed conversion ratio than those in the control group
31 ($p < 0.05$). In trial II (immune response and disease resistance experiment), the Nile tilapia
32 received the same experimental diets as in Trial I, also for 4 weeks. At 2 and 4 weeks of
33 treatment, the fish receiving cells at a concentration of 1.5 g/kg or extracts at 7.5 mg/kg had
34 significantly higher haematocrit, phagocytic activity and phagocytic index than the fish in
35 the control group ($p < 0.05$). Moreover, all treatments with dietary supplements had
36 significantly lower mortality rate than in the control group ($p < 0.05$) when challenged with *S.*
37 *agalactiae* by immersion method. The present study demonstrated that dietary administration
38 of *Z. marina* cells at a concentration of 1.5 g/kg or extract at a concentration of 7.5 mg/kg
39 improved growth, immune response, as well as disease resistance against *S. agalactiae* in
40 Nile tilapia.

42 **Keywords:** Nile tilapia; *Zooshikella marina*; growth; immune response; *Streptococcus*
43 *agalactiae*

44

45 **1. Introduction**

46 Nile tilapia (*Oreochromis niloticus*) is an important economic fish cultured
47 worldwide. At present, tilapia culture has rapidly expanded in Thailand due to its high
48 economic value as well as its consumer acceptance. However, farmers have changed their
49 culture practices from an extensive to an intensive culture system in order to meet the
50 growing demand in domestic as well as international markets. As a result, effective farm
51 management practices are essential, particularly in terms of disease prevention. Nowadays,
52 streptococcosis caused by *Streptococcus agalactiae* can be highly devastating and is
53 responsible for larger economic losses in tilapia cultures worldwide (Suanyuk, Kong, Ko,
54 Gilbert, & Supamattaya, 2008; Ye *et al.*, 2011; Zamri-Saad, Amal, Siti-Zahrah, & Zulkafli,
55 2014). At present, *S. agalactiae* is divided into ten serotypes (Ia, Ib, II, III, IV, V, VI, VII,
56 VIII and IX) based on the composition of its capsular polysaccharide (Slotved, Kong,
57 Lambertsen, Sauer, & Gilbert, 2007). In Thailand, *S. agalactiae* serotypes Ia, Ib and III have
58 caused serious damage in tilapia, climbing perch (*Anabas testudineus*), and Günther's
59 walking catfish (*Clarias macrocephalus*), when farmed in cages or in earthen ponds
60 (Dangwetngam, Suanyuk, Kong, & Phromkunthong, 2016; Klingklib & Suanyuk, 2017;
61 Klingklib, Suanyuk, Kongkapan, & Tantikitti, 2021; Suanyuk *et al.*, 2008). The clinical signs
62 exhibited by infected fish include lethargy, loss of appetite, erratic swimming, corneal
63 opacity, exophthalmia, and hemorrhaging of the internal organs (Klingklib & Suanyuk, 2017;

64 Suanyuk, Kangheae, Khongpradit, & Supamattaya, 2005; Suanyuk *et al.*, 2008;
65 Suwannasang, Dangwetngam, Issaro, Phromkunthong, & Suanyuk, 2014). Currently,
66 prevention and control of infectious diseases relies mostly on application of antibiotics and
67 chemicals. However, the use of antibiotics is becoming limited due to the impacts on fish
68 performance and welfare, as well as to increased environmental contamination with antibiotic
69 residues or antibiotic resistant bacteria. Recently, many studies have focused on
70 identification and characterization of secondary metabolites with pharmaceutical potential
71 from marine bacteria, including *Pseudoalteromonas rubra* (Setiyono *et al.*, 2020), *Hahella*
72 *chejuensis* (Lee *et al.*, 2001), *Serratia marcescens* (Lapenda, Silva, Vicalvi, Sena, &
73 Nascimento, 2015) and *Zooshikella ganghwensis* (Yi, Chang, Oh, Bae, & Chun, 2003). *Z.*
74 *marina* was first isolated from a beach sand sample in India, and the major pigments
75 produced by this bacterium were identified as prodigiosin and cycloprodigiosin
76 (Ramaprasad, Bharti, Sasikala, & Ramana, 2015). Prodigiosin possesses many bioactivities,
77 such as anti-bacterial, immunosuppressive, anti-diabetic, and anti-cancer activities (Yi *et al.*,
78 2003). Previous studies have indicated that prodigiosin inhibits both Gram-positive and
79 Gram-negative bacteria (Lapenda *et al.*, 2015; Lee *et al.*, 2011). On the other hand,
80 cycloprodigiosin is produced only as a minor component by some marine bacteria (Kawauchi
81 *et al.*, 1997; Lee *et al.*, 2011; Ramaprasad *et al.*, 2015). Although *in vitro* studies on the
82 inhibitory effects of prodigiosin and cycloprodigiosin have been reported, little is known
83 about the *in vivo* effect of cells or extracts from this prodigiosin and cycloprodigiosin
84 producing marine bacterium. Therefore, the purpose of this study was to investigate the *in*
85 *vivo* effects of cells and extracts from *Z. marina* on the growth performance, immune

86 responses and disease resistance of Nile tilapia against *S. agalactiae* infection. The results
87 from this study will be useful for the fish farmers, helping prevent bacterial diseases in a
88 sustainable way.

89

90 **2. Materials and Methods**

91 **2.1 Ethics statement**

92 This study was performed in accordance with the “Ethical Principles and Guidelines
93 for the Use of Animals for Scientific Purposes”, National Research Council, Thailand, and it
94 was approved by the Institutional Animal Care and Use Committee, Prince of Songkla
95 University, under permission numbers Ref. 12/2020 and Ref. AQ016/2022.

96 **2.2 Preparation of *Z. marina* extract**

97 The ethanolic extraction of *Z. marina* isolated from marine sponge was carried out
98 according to the method described previously. Briefly, *Z. marina* cultured on marine agar
99 (MA) was transferred into marine broth (MB) and incubated at 30°C with 200 rpm agitation
100 for 48 h. Bacterial cells were then harvested by centrifugation at 10,000 rpm at 4°C for 10
101 min, and washed 3 times with 0.85% sterile saline. Bacterial cells were then freeze-dried and
102 cell pellets were repeatedly crushed in 95% ethanol using a mortar and pestle, until the
103 solution was clear and colorless. The suspension was filtered with filter paper and the filtrate
104 was evaporated using a rotary evaporator until a dry red powder was obtained (Puangpee &
105 Suanyuk, 2021). The extract was stored in an amber glass bottle at -20°C until use.

106 **2.3 Preparation of diets**

107 Experimental diet was formulated to be isonitrogenous at 36%, and isolipidic at 8.5%,
108 with fishmeal as the major protein source to satisfy the nutrient requirements of Nile tilapia.
109 Furthermore, soybean meal, wheat flour, fish oil, soybean oil, alpha-starch, a vitamin and
110 mineral mixture, inositol, choline chloride, and di-calcium phosphate were used as
111 ingredients of the basal diet (Table 1). The sinking pellets with a diameter of 2.0 mm were
112 processed using HOBART machine (LEGACY[®], OH, USA), oven-dried at 60 °C and stored
113 at -20 °C. Feed samples were analyzed for their proximate chemical compositions, using the
114 procedures of Association of Official Analytical Chemists (AOAC, 1995) (Table 1). Before
115 the experiment, the prepared feed was mixed with *Z. marina* cells and extracts at
116 concentrations of 0.5, 1.0 and 1.5 g/kg and 2.5, 5.0 and 7.5 mg/kg, respectively. The feed
117 pellets supplemented with *Z. marina* cells and extracts were then spray-coated with fish oil
118 to prevent the leaching of *Z. marina* cells and extracts during the feeding process, while the
119 control diet was spray-coated with fish oil only. All experimental diets were then air-dried
120 under sterile conditions in a laminar airflow chamber and stored at -20 °C until use.
121 Prodigiosin content in the diet was quantified spectrophotometrically according to the
122 methods modified from Puangpee and Suanyuk (2021) and Lin *et al.* (2019). Briefly, the
123 pellets were properly diluted with ethanol and crushed using a mortar and pestle. The solution
124 was filtered with filter paper (Whatman, No. 42) and the absorbance at 535 nm was then
125 measured. Prodigiosin content in the sample was calculated using a calibration curve for
126 purified prodigiosin hydrochloride from *S. marcescens* (98% (HPLC), powder, Sigma) as the
127 standard. The actual concentrations of prodigiosin in the seven experimental diets were
128 0.00±0.00, 0.49±0.01, 0.97±0.01, 1.49±0.02, 2.08±0.05, 4.18±0.04 and 6.59±0.02 mg/kg,
129 respectively.

130 **2.4 Experimental animals**

131 Healthy Nile tilapia with an initial body weight of approximately 15 g were obtained
132 from a commercial fish farm in Pak Phanang district, Nakhon Si Thammarat province,
133 Thailand. During the acclimatization period, the fish were reared in fiberglass tanks under
134 continuous aeration, and they were fed a commercial diet twice daily to satiation until an
135 individual weight of about 18 g was achieved. Before starting the experiment, test fish were
136 sampled and examined to ensure that they were streptococcosis-free prior to use in the
137 experiment.

138 **2.5 Trial I: Growth performance experiment**

139 Eight hundred and forty Nile tilapia were used in this study. The experimental fish
140 were randomly distributed into twenty-four aquaria (50 cm width × 120 cm length × 50 cm
141 height) each containing 200 L dechlorinated water. Seven treatment groups of fish (40 fish
142 each × 3 replicates) were fed with different *Z. marina* cells and extracts as follows: T1
143 (Control diet, without supplemented *Z. marina* cells or extracts), T2 (*Z. marina* cells 0.5
144 g/kg), T3 (*Z. marina* cells 1.0 g/kg), T4 (*Z. marina* cells 1.5 g/kg), T5 (*Z. marina* extracts 2.5
145 mg/kg), T6 (*Z. marina* extracts 5.0 mg/kg) and T7 (*Z. marina* extracts 7.5 mg/kg) to satiation
146 twice daily at 8.30 a.m. and 4.30 p.m. During the experiment, the water quality parameters
147 temperature, total alkalinity, pH, dissolved oxygen, ammonia, and nitrite were analyzed by
148 standard methods (Boyd & Tucker, 1992).

149 At 2 and 4 weeks of the feeding trial, all the fish in each tank were fasted for 24h, and
150 then counted and weighed after being anesthetized with 0.05 mL/L clove oil (Hamackova,

151 Kouril, Kozak, & Stupka, 2006). The weight measurements and fish counts were used to
152 calculate weight gain, specific growth rate, feed conversion ratio, and survival rate (Maniat,
153 Ghotbeddin, & Ghatrami, 2014). The growth performance indicators were calculated as
154 follows:

155 $\text{Weight gain (\%)} = (\text{final weight} - \text{initial weight}) \times 100$

156 $\text{Specific growth rate} = [(\text{Ln of final weight} - \text{Ln of initial weight}) / t \text{ (time interval in days)}]$
157 $\times 100$

158 $\text{Feed conversion ratio} = \text{feed intake (as fed basis)} / \text{weight gain}$

159 $\text{Survival rate (\%)} = (\text{Final number of fish} / \text{Initial number of fish}) \times 100$

160 **2.6 Trial II: Immune responses and disease resistance**

161 **2.6.1 Experimental fish and feeding trials**

162 Nine hundred and sixty Nile tilapia with an average weight of 18.86 ± 2.99 g were used
163 in this study. The experimental fish were randomly distributed into twenty-four aquaria (50
164 cm width \times 120 cm length \times 50 cm height) each containing 200 L dechlorinated water. Eight
165 treatment groups of fish (40 fish each \times 3 replicates) were fed with different *Z. marina* cells
166 and extracts as follows: T1 and T2 (Control diet, without supplemented *Z. marina* cells or
167 extracts), T3 (*Z. marina* cells 0.5 g/kg), T4 (*Z. marina* cells 1.0 g/kg), T5 (*Z. marina* cells 1.5
168 g/kg), T6 (*Z. marina* extracts 2.5 mg/kg), T7 (*Z. marina* extracts 5.0 mg/kg) and T8 (*Z.*
169 *marina* extracts 7.5 mg/kg) to satiation twice daily at 8.30 a.m. and 4.30 p.m. for 4 weeks.

170 **2.6.2 Haemato-immunological parameters**

171 At 2 and 4 weeks of the feeding trial, 3 fish from each replication (9 fish/treatment)
172 were randomly sampled and anaesthetized with clove oil. The blood was collected from
173 caudal vein/artery for haemato-immunological analyses. Red blood cells and white blood
174 cells were counted using a Bright-Line™ Haemocytometer (Hausser Scientific, USA) under
175 a compound microscope, haemoglobin level was measured colorimetrically by determining
176 the formation of cyanmet-haemoglobin, and haematocrit was examined using heparinized
177 micro-haematocrit capillary tube (Vitrex, Denmark) following a method of Suwannasang *et*
178 *al.* (2014). The nitroblue tetrazolium (NBT) reduction was assayed using the modified
179 method of Stasiak and Baumann (1996). For the quantification of serum protein,
180 immunoglobulin and lysozyme, fish blood was centrifuged at 5,000 rpm for 10 min at 4°C,
181 and the supernatant (serum) was transferred into a new microcentrifuge tube. Total serum
182 protein was quantified colorimetrically following the method of Lowry, Rosebrough, Farr,
183 and Randall (1951). Immunoglobulin was analyzed from total serum protein with subtraction
184 of non-immunoglobulin protein, by the method of Siwicki, Anderson and Rumsey (1994).
185 Lysozyme was measured based on a turbidimetric microplate assay using *Micrococcus*
186 *lysodeikticus* (Sigma, USA) suspension as a substrate (Demers & Bayne, 1997). For
187 determination of the phagocyte responses to foreign substances, head kidney leucocytes were
188 isolated using an aseptic technique. Phagocytic activity, phagocytic index, and average bead
189 ingested per cell were measured following the methods of Klinglib *et al.* (2021).

190 **2.6.3 *In vivo* immersion challenge test**

191 At 2 and 4 weeks of the feeding trial, seven of the eight treatment groups (T2-T8)
192 were challenged with *S. agalactiae* serotype Ia while the remaining treatment group (T1)

193 served as a not challenged control. The combined effect of high temperature and hypoxia on
194 immersion challenge with *S. agalactiae* was conducted in this study using the modified
195 method of He, Li, Li, and Li (2021). Briefly, *S. agalactiae* grown at 30°C for 18 h on tryptic
196 soy agar (TSA) were scraped using a sterile loop, resuspended and adjusted to 10⁸ CFU/mL
197 with phosphate buffer saline (PBS). Subsequently, 10 fish from each replication were
198 transferred from culture tanks to their assigned challenge tanks containing *S. agalactiae*
199 suspension. After 2 h of exposure, the fish were moved from the challenge tank to glass tanks
200 (45 cm width x 90 cm length x 45 cm height) containing 100 L dechlorinated water under
201 stress condition of an elevated temperature (32±0.5°C) combined with low dissolved oxygen
202 (DO) (2.05±0.53 ppm). The experiment was carried out in triplicate and results were
203 compared to two control groups, i.e., T1 as non-challenged control group where the
204 experimental fish were immersed in PBS, and T2 as a challenged control group where the
205 experimental fish were immersed in *S. agalactiae* suspension. Clinical signs and mortality
206 were recorded for 14 days. The tissue of the brain obtained from all the dead fish was
207 inoculated onto TSA to re-isolate bacteria and verify the streptococcal infection.

208 **2.7 Statistical analysis**

209 Data are reported as means ± standard deviations. Percentage data were subjected to
210 arcsine transformation prior to an analysis of variance. Significant differences in growth
211 performance, haemato-immunological parameters and cumulative mortalities were analyzed
212 using one-way analysis of variance (ANOVA) and differences between treatments were
213 analyzed using Duncan's multiple range test and were considered significant at p<0.05.

214

215 3. Results and Discussion

216 3.1 Trial I: Growth performance experiment

217 After 2 weeks of the feeding trial, the fish receiving dietary supplementation with 1.5
218 g/kg cells or 7.5 mg/kg extract had significantly higher final weight and weight gain than the
219 control group ($p < 0.05$). Moreover, the fish receiving cells or extracts at any concentration
220 had significantly better specific growth rate and feed conversion ratio than the control group
221 ($p < 0.05$, Table 2). Similarly, after 4 weeks of the feeding trial, fish receiving cells or extract
222 at any concentration showed significantly better final weight, weight gain, specific growth
223 rate, and feed conversion ratio than the control group ($p < 0.05$). No significant difference was
224 found in survival rate between the actual treatments and the control after 2 or 4 weeks of the
225 feeding trial ($p > 0.05$, Table 2). Water quality during the experiment was at an acceptable
226 level consistently, with temperature from $27.80 \pm 0.40^\circ\text{C}$ to $28.20 \pm 0.36^\circ\text{C}$, total alkalinity
227 from 22.67 ± 9.81 mg/L to 28.33 ± 9.81 mg/L, pH from 7.17 ± 0.06 to 7.40 ± 0.17 , dissolved
228 oxygen from 5.57 ± 0.15 mg/L to 6.13 ± 0.06 mg/L, and total ammonia were below 0.1 mg/L.
229 In this study, experimental diets were prepared to contain 36% protein and 8.5% fat, which
230 was apparently similar as in Afuang, Siddhuraja, and Becker (2003) who prepared the
231 experimental diets for tilapia to contain 36.2% crude protein and 8.9% crude lipid. The
232 growth of Nile tilapia fed with the control diet supports that diet as suitable for these
233 experiments. Furthermore, Nile tilapia fed 1.5 g/kg cells or 7.5 mg/kg extract showed
234 significantly better growth performance than in the control group at 2 or 4 weeks, indicating
235 that *Z. marina* cells and extracts improved fish growth. This is consistent with Kim,
236 Harikrishnan, Kim, Balasundaram, and Heo (2010), who demonstrated that olive flounder

237 (*Paralichthys olivaceus*) fed *Zooshikella* sp. cells had higher weight gain than the fish
238 receiving the control diet. Similarly, Nile tilapia fed with experimental diet containing
239 0.48×10^6 CFU/g *Bacillus licheniformis* and 1.0% yeast extract showed the highest final body
240 weight, weight gain, specific growth rate, best feed conversion ratio, protein efficiency ratio
241 and protein productive value (Hassaan, Soltan, & Ghonemy, 2014).

242 3.2 Trial II: Immune responses and disease resistance

243 3.2.1 Haemato-immunological parameters

244 After 2 weeks of the feeding trial, the fish receiving dietary supplementation with 1.5
245 g/kg cells had significantly higher red blood cell, white blood cell, haemoglobin, haematocrit
246 and NBT reduction than the control group ($p < 0.05$). Moreover, the fish receiving dietary
247 supplementation with 7.5 mg/kg of extract had significantly higher haemoglobin, haematocrit
248 and serum protein than in the control treatment ($p < 0.05$). No significant differences were
249 found in immunoglobulin and lysozyme between the actual treatments and the control groups
250 ($p > 0.05$, Table 3). Besides, the fish receiving supplementation with 1.5 g/kg cells or 7.5
251 mg/kg extract had significantly higher phagocytic activity and phagocytic index than the
252 control group ($p < 0.05$, Figure 1a-b). No significant difference was found in average bead
253 ingested per cell in comparison to the control groups ($p > 0.05$, Figure 1c).

254 After 4 weeks of the feeding trials, the fish receiving 1.5 g/kg cells in the feed had
255 significantly higher white blood cell, haemoglobin, haematocrit and serum protein than the
256 control group ($p < 0.05$). Also, fish fed with dietary supplementation of 7.5 mg/kg extract had
257 significantly higher red blood cell, haematocrit and serum protein than the control group

258 (p<0.05). No significant differences were found in NBT reduction, immunoglobulin and
259 lysozyme between the actual treatments and the control groups (p>0.05, Table 4). In addition,
260 the fish receiving 1.5 g/kg cells or 7.5 mg/kg extract had significantly higher phagocytic
261 activity and phagocytic index than the control groups (p<0.05, Figure 2a-b). No significant
262 difference was found in average bead ingested per cell between the treatments and the control
263 groups (p>0.05, Figure 2c).

264 The use of the haemato-immunological parameters red blood cell, white blood cell,
265 haemoglobin, haematocrit, and serum protein to monitor fish growth and health has proven
266 to be effective and repeatable (Esmaeili, 2021). Better growth performance of Nile tilapia
267 with any of the supplemented diets (cells or extract from *Z. marina*) in the present study
268 support this aspect. Basically, red blood cells are in charge of transporting oxygen; white
269 blood cells are involved in both specific and non-specific immune responses; haemoglobin
270 is in charge of aerobic metabolism, which involves binding oxygen, dissolving gas, and
271 transporting them to the tissues; haematocrit is in charge of viscosity, which is beneficial for
272 health; and serum proteins is involved in a wide range of functions, including maintaining
273 osmotic pressure, pH, transporting various metabolites, and interacting with the immune
274 system (Esmaeili, 2021). Decreased haemato-immunological parameters were reported in
275 Nile tilapia infected with *S. agalactiae* (Suanyuk *et al.*, 2005). The results from the current
276 study is, however, consistent with previous study that Nile tilapia fed with dietary
277 supplementation with 1g/kg *Aspergillus oryzae*, 1g/kg β -glucan, and 0.5 g/kg *A. oryzae* + 0.5
278 g/kg β -glucan exhibited significantly higher haematocrit, hemoglobin, white blood cells, red
279 blood cells and phagocytic activity than those in the control group (p<0.05) while NBT

280 reduction and phagocytic index increased significantly ($p < 0.05$) in fish fed 1 g/kg *A. oryzae*
281 and 0.5 g/kg *A. oryzae* + 0.5 g/kg β -glucan over the control (Dawood, Eweedah, Moustafa,
282 & Shahin, 2020). Similarly, highest value of haemoglobin, haematocrit, red blood cell and
283 white blood cell was observed in Nile tilapia fed with 0.48×10^6 CFU/g *B. licheniformis* and
284 0.5% yeast extract (Hassaan *et al.*, 2014). The results from the present study indicated that
285 dietary supplementation with *Z. marina* cells at a concentration of 1.5 g/kg or the extract at
286 a concentration of 7.5 mg/kg can be stimulated the innate immune system in Nile tilapia.

287

288 **3.2.2 *In vivo* immersion challenge assay**

289 A variety of infection method including injection, immersion, oral administration,
290 and cohabitation has been used for evaluation of disease in tilapia infection with *S. agalactiae*
291 (Suanyuk *et al.*, 2008; Mian, Godoy, Leal, Yuhara, Costa, & Figueiredo, 2009; Rodkhum,
292 Kayansamruaj, & Pirarat, 2011; Suwannasang *et al.*, 2014; Soto, Zayas, Tobar, Illanes,
293 Yount, Francis, & Dennis, 2016; He *et al.*, 2021). The route of immersion infection closely
294 resembles natural infection because gill, skin, and gastrointestinal tract are the three major
295 entry routes of pathogens in fish (Ling, Wang, Lim, & Leung, 2001; Wu, Zhang, Lin, Hao,
296 Wang, Zhang, & Li, 2021). However, the immersion challenge could not maintain high
297 mortality rate compared to an injection challenge (Soto *et al.*, 2016). Hence, the combined
298 effect of high temperature and hypoxia as a synergistic stressor on immersion challenge with
299 *S. agalactiae* was conducted in this study using the modified method of He *et al.* (2021).
300 After 2 weeks of the feeding trial, the cumulative mortalities of experimental fish immersed
301 with *S. agalactiae* were 6.67, 10.00 and 3.33% for the fish fed with dietary supplementation

302 of 0.5, 1.0 and 1.5 g/kg cells; and the mortalities were 13.33, 10.00 and 3.33% in fish fed
303 with dietary supplementation of 2.5, 5.0 and 7.5 mg/kg extract. These were significantly
304 lower ($p < 0.05$) than the infected control group (36.67%). No mortality was observed in the
305 non-challenged control group (Figure 3). After 4 weeks of the feeding trial, the cumulative
306 mortality of experimental fish immersed with *S. agalactiae* was 0.00% when receiving
307 dietary supplementation with cells at any concentration; and the cumulative mortalities were
308 16.67, 10.00 and 0.00% in fish receiving 2.5, 5.0 and 7.5 mg/kg extract, whereas significantly
309 higher cumulative mortality of 36.67% was recorded for the infected control group ($p < 0.05$).
310 No mortality was found in non-challenged control group (Figure 4).

311 Kim *et al.* (2010) revealed that the cumulative mortality was low in infected fish
312 receiving dietary supplementation with a high level of *Zooshikella* sp. cells. Resistance of
313 the experimental fish against *S. agalactiae* infection observed in this current study may be
314 due to prodigiosin and cycloprodigiosin that inhibit pathogenic bacteria. The antibacterial
315 activity of prodigiosin is due to its ability to pass through and damage the cell membrane, as
316 well as its capacity for inhibiting target enzymes involved in DNA replication, such as
317 topoisomerase IV and DNA gyrase (Berlanga, Ruiz, & Hernandez-Borrell, 2000; Darshan &
318 Manonmani, 2016), as well as potentially interfering with certain steps in the pathogenic
319 process by decreasing invasion into the fish target organ (Puangpee & Suanyuk, 2021). In
320 addition, the enhancement of haemato-immunological parameters by dietary
321 supplementation with *Z. marina* diets observed in this study may possibly an important factor
322 in reducing the percentage of mortality and thereby protecting the fish against *S. agalactiae*
323 infection.

324 During challenge test, Nile tilapia received the control diet infected with *S. agalactiae*
325 (T2) exhibited erratic swimming, an increased opercular movement, darkening skin, eye
326 opacity, eye exophthalmia, and ascites. Few clinical signs were observed in some fish
327 received dietary supplementation with cells and extract from *Z. marina*. *S. agalactiae* was
328 re-isolated from the brain of all dead fish indicating that the deaths were caused by
329 streptococcal infection. This is consistent with several reports that fish infected with *S.*
330 *agalactiae* exhibited similar symptoms typical of streptococcosis (Klingklib & Suanyuk,
331 2017; Suanyuk *et al.*, 2008; Suwannasang *et al.*, 2014). However, it should be noted that the
332 environmental factors may play an important role, equal to or dominant over the host and
333 pathogenic factors, as regards disease pathogenesis (Chen & He, 2019). The accumulated
334 mortality of tilapia immersion challenged with *S. agalactiae* at concentration of 10^8 CFU/mL
335 was highest in the group maintained at 33°C followed by 30°C and 25°C. (Rodkhum *et al.*,
336 2011). Moreover, He *et al.* (2021) reported a high mortality in tilapia infected with *S.*
337 *agalactiae* by immersion challenge when exposed to an elevated temperature ($33.5 \pm 0.5^\circ\text{C}$)
338 and hypoxia (2.0 ± 0.5 mg/l dissolved oxygen) indicating that improper environmental factors
339 such as high water temperature and hypoxia play important roles in disease pathogenesis.

340

341 **4. Conclusions**

342 In summary, *Z. marina* cells and extracts promote the growth of Nile tilapia. In
343 addition, the enhancement of innate immune parameters by *Z. marina* cells and extracts is a
344 possibly important factor reducing mortality and protecting the fish against *S. agalactiae*
345 infection. Furthermore, the dietary administration of *Z. marina* cell at a concentration of 1.5

346 g/kg or of the extract at a concentration of 7.5 mg/kg could be used to promote growth,
347 stimulate immune responses, as well as to protect the fish against streptococcosis caused by
348 *S. agalactiae* infection.

349

350 **Acknowledgments**

351 This work was financially supported by a research fund from the Agricultural
352 Research Development Agency (Public Organization) under the Grant No. CRP6305031780.
353 The authors thank Wanwisa Sangwong and Suppanat Thaneerat for assistance in conducting
354 the experiments.

355

356 **References**

357 Afuang, W., Siddhuraju, P., & Becker, K. (2003). Comparative nutritional evaluation of raw,
358 methanol extracted residues and methanol extracts of moringa (*Moringa oleifera*
359 Lam.) leaves on growth performance and feed utilization in Nile tilapia
360 (*Oreochromis niloticus* L.). *Aquaculture Research*, 34(13), 1147-1159. doi:
361 10.1046/j.1365-2109.2003.00920.x.

362 Association of Official Analytical Chemists. (1995). *Official methods of analysis of AOAC*
363 *International* (16th ed.). Association of Analytical Communities, Arlington, VA:
364 Cunniff, P.A.

365 Berlanga, M., Ruiz, N., & Hernandez-Borrell, J. (2000). Role of the outer membrane in the
366 accumulation of quinolones by *Serratia marcescens*. *Canadian Journal of*
367 *Microbiology*, 46(8), 716–722. doi: 10.1139/w00-052.

368 Boyd, C. E., & Tucker C. S. (1992). *Water quality and pond soil analyses for aquaculture*.
369 Alabama Agricultural Experiment Station, Auburn University, Alabama: Authors.

370 Chen, Y.H., & He, J.G. (2019). Effects of environmental stress on shrimp innate immunity
371 and white spot syndrome virus infection. *Fish and Shellfish Immunology*, 84, 744–
372 755. doi: 10.1016/j.fsi.2018.10.069.

373 Dangwetngam, M., Suanyuk, N., Kong, F., & Phromkunthong, W. (2016). Serotype
374 distribution and antimicrobial susceptibilities of *Streptococcus agalactiae* isolated
375 from infected cultured tilapia (*Oreochromis niloticus*) in Thailand: Nine-year
376 perspective. *Journal of Medical Microbiology*, 65(3), 247-254. doi.
377 10.1099/jmm.0.000213.

378 Darshan, N., & Manonmani, H.K. (2016). Prodigiosin inhibits motility and activates bacterial
379 cell death revealing molecular biomarkers of programmed cell death. *AMB Express*,
380 6(1), 50. doi: 10.1186/s13568-016-0222-z.

381 Dawood, M.A.O., Eweedah, N.M., Moustafa, E.M., & Shahin, M.G. (2020). Synbiotic
382 effects of *Aspergillus oryzae* and β -glucan on growth and oxidative and immune
383 responses of Nile tilapia, *Oreochromis niloticus*. *Probiotics and Antimicrobial*
384 *Proteins*, 12, 172-183. doi: 10.1007/s12602-018-9513-9.

- 385 Demers, N.E., & Bayne, C.J. (1997). The immediate effects of stress on hormones and
386 plasma lysozyme in rainbow trout. *Developmental and Comparative Immunology*,
387 21(4), 363-373. doi: 10.1016/S0145-305X(97)00009-8.
- 388 Esmaeili, M. (2021). Blood performance: A new formula for fish growth and health. *Biology*,
389 10(12), 1236. doi: 10.3390/biology10121236.
- 390 Hamackova, J., Kouril, J., Kozak, P., & Stupka, Z. (2006). Clove oil as an anaesthetic for
391 different freshwater fish species. *Bulgarian Journal of Agricultural Science*, 12(2),
392 185-194. Retrieved from <http://www.agrojournal.org/12/02-04-06.pdf>
- 393 Hassaan, M.S., Soltan, M.A., & Ghonemy, M.M.R. (2014). Effect of synbiotics between
394 *Bacillus licheniformis* and yeast extract on growth, hematological and biochemical
395 indices of the Nile tilapia (*Oreochromis niloticus*). *Egyptian Journal of Aquatic
396 Research*, 40(2), 199-208. doi: 10.1016/j.ejar.2014.04.001.
- 397 He, R.Z., Li, Z.C., Li, S.Y., & Li, A.X. (2021). Development of an immersion challenge
398 model for *Streptococcus agalactiae* in Nile tilapia (*Oreochromis niloticus*).
399 *Aquaculture*, 531, 735877. doi: 10.1016/j.aquaculture.2020.735877.
- 400 Kawauchi, K., Shibutani, K., Yagisawa, H., Kamata, H., Nakatsuji, S., Anzai, H., Yokoyama,
401 Y., Ikegami, Y., Moriyama, Y., & Hirata, H. (1997). A possible
402 immunosuppressant, cycloprodigiosin hydrochloride, obtained from
403 *Pseudoalteromonas denitrificans*. *Biochemical and Biophysical Research
404 Communications*, 237(3), 543-547. doi: 10.1006/bbrc.1997.7186.

- 405 Kim, J.S., Harikrishnan, R., Kim, M.C., Balasundaram C., & Heo, M.S. (2010). Dietary
406 administration of *Zooshikella* sp. enhance the innate immune response and disease
407 resistance of *Paralichthys olivaceus* against *Streptococcus iniae*. *Fish and Shellfish*
408 *Immunology*, 29(1), 104-110. doi: 10.1016/j.fsi.2010.02.022.
- 409 Klingklib, C., & Suanyuk, N. (2017). *Streptococcus agalactiae* serotype Ib, an emerging
410 pathogen affecting climbing perch (*Anabas testudineus*) and Günther's walking
411 catfish (*Clarias macrocephalus*) polycultured in southern Thailand. *The Thai*
412 *Journal of Veterinary Medicine*, 47(2), 183-197. Retrieved from [https://he01.tci-](https://he01.tci-thaijo.org/index.php/tjvm/article/view/90276)
413 [thaijo.org/index.php/tjvm/article/view/90276](https://he01.tci-thaijo.org/index.php/tjvm/article/view/90276)
- 414 Klingklib, C., Suanyuk, N., Kongkapan, T., & Tantikitti, C. (2021). Epizootiology,
415 pathogenicity and haemato-immunology associated with *Streptococcus agalactiae*
416 serotype Ib infection in climbing perch (*Anabas testudineus*). *Songklanakarin*
417 *Journal of Science and Technology*, 43(4), 1212-1219. doi: 10.14456/sjst-
418 psu.2021.158.
- 419 Lapenda, J.C., Silva, P.A., Vicalvi, M.C., Sena, K.X.F.R., & Nascimento, S.C. (2015).
420 Antimicrobial activity of prodigiosin isolated from *Serratia marcescens* UFPEDA
421 398. *World Journal of Microbiology and Biotechnology*, 31(2), 399-406. doi:
422 10.1007/s11274-014-1793-y.
- 423 Lee, H.K., Chun, J., Moon, E.Y., Ko, S.K., Lee, D.S., Lee, H.S., & Bae, K.S. (2001). *Hahella*
424 *chejuensis* gen. nov., sp. nov., an extracellular-polysaccharide-producing marine

425 bacterium. *International Journal of Systematic and Evolutionary Microbiology*,
426 51(2), 661-666. doi: 10.1099/00207713-51-2-661.

427 Lee, J.S., Kim, Y.S., Park, S., Kim, J., Kang, S.J., Lee, M.H., Ryu, S., Choi, J.M., Oh, T.K.,
428 & Yoon, J. H. (2011). Exceptional production of both prodigiosin and
429 cycloprodigiosin as major metabolic constituents by a novel marine bacterium,
430 *Zooshikella rubidus* S1-1. *Applied and Environmental Microbiology*, 77(14), 4967-
431 4973. doi: 10.1128/AEM.01986-10.

432 Lin, C., Jia, X., Fang, Y., Chen, L., Zhang, H., Lin, R., & Chen, J. (2019). Enhanced
433 production of prodigiosin by *Serratia marcescens* FZSF02 in the form of pigment
434 pellets. *Electronic Journal of Biotechnology*, 40, 58-64. doi:
435 10.1016/j.ejbt.2019.04.007.

436 Ling, S.H.M., Wang, X., H., Lim, T.M., & Leung, K.Y. (2001). Green fluorescent protein-
437 tagged *Edwardsiella tarda* reveals portal of entry in fish. *FEMS Microbiology*
438 *Letters*, 194(2), 239-243. doi: 10.1016/S0378-1097(00)00498-5.

439 Lowry, O.H., Rosebrough, N.J., Farr, A.L., & Randall, R.J. (1951). Protein measurement
440 with the Folin-Phenol reagents. *Journal of Biological Chemistry*, 193(1), 265-275.
441 doi: 10.1016/S0021-9258(19)52451-6.

442 Maniat, M., Ghotbeddin, N., & Ghatrami, E.R. (2014). Effect of garlic on growth
443 performance and body composition of benni fish (*Mesopotamichthys*
444 *sharpeyi*). *International Journal of Biosciences*, 5(4), 269-277. doi:
445 10.12692/ijb/5.4.269-277.

446 Mian, G.F., Godoy, D.T., Leal, C.A.G., Yuhara, T.Y., Costa, G.M., & Figueiredo, H.C.P.
447 (2009). Aspects of the natural history and virulence of *S. agalactiae* infection in Nile
448 tilapia. *Veterinary Microbiology*, 136(1-2), 180-183. doi:
449 10.1016/j.vetmic.2008.10.016.

450 Puangpee, S., & Suanyuk, N. (2021). *In vitro* and *in vivo* evaluation of antimicrobial activity
451 of *Zooshikella marina* against pathogenic bacteria causing vibriosis in aquaculture.
452 *Aquaculture Research*, 52(10), 4996–5007. doi: 10.1111/are.15371.

453 Ramaprasad, E.V.V., Bharti, D., Sasikala, C.H., & Ramana, C.V. (2015). *Zooshikella marina*
454 sp. nov. a cycloprodigiosin-and prodigiosin-producing marine bacterium isolated
455 from beach sand. *International Journal of Systematic and Evolutionary*
456 *Microbiology*, 65(12), 4669-4673. doi: 10.1099/ijsem.0.000630.

457 Rodkhum, C., Kayansamruaj, P., & Pirarat, N. (2011). Effect of Water Temperature on
458 Susceptibility to *Streptococcus agalactiae* Serotype Ia Infection in Nile Tilapia
459 (*Oreochromis niloticus*). *Thai Journal of Veterinary Medicine*, 41(3), 309-314.
460 Retrieved from <https://digital.car.chula.ac.th/tjvm/vol41/iss3/7/>

461 Setiyono, E., Adhiwibawa, M.A.S., Indrawati, R., Prihastyanti, M.N.U., Shioi, Y., &
462 Brotosudarmo, T.H.P. (2020). An Indonesian Marine Bacterium,
463 *Pseudoalteromonas rubra*, Produces Antimicrobial Prodiginine Pigments. *ACS*
464 *omega*, 5(9), 4626–4635. doi: 10.1021/acsomega.9b04322.

465 Siwicki, A.K., Anderson, D.P., & Rumsey, G.L. (1994). Dietary intake of immunostimulants
466 by rainbow trout affects nonspecific immunity and protection against furunculosis.

467 *Veterinary Immunology and Immunopathology*, 41(1-2), 125-139. doi:
468 10.1016/0165-2427(94)90062-0.

469 Slotved, H.C., Kong, F., Lambertsen, L., Sauer, S., & Gilbert, G.L. (2007). Serotype IX, a
470 proposed new *Streptococcus agalactiae* serotype. *Journal of Clinical Microbiology*,
471 45(9), 2929-2936. doi: 10.1128/JCM.00117-07.

472 Soto, E., Zayas, M., Tobar, J., Illanes, O., Yount, S., Francis, S., & Dennis, M.M. (2016).
473 Laboratory-controlled challenges of Nile tilapia (*Oreochromis niloticus*) with
474 *Streptococcus agalactiae*: Comparisons between immersion, oral, intracoelomic
475 and intramuscular routes of infection. *Journal of Comparative Pathology*, 155(4),
476 339-345. doi: 10.1016/j.jcpa.2016.09.003.

477 Stasiak, S.A., & Baumann, P.C. (1996). Neutrophil activity as a potential bioindicator for
478 contaminant analysis. *Fish and Shellfish Immunology*, 6(7), 537-539. doi:
479 10.1006/fsim.1996.0050.

480 Suanyuk, N., Kangheae, H., Khongpradit, R., & Supamattaya, K. (2005). *Streptococcus*
481 *agalactiae* infection in Tilapia (*Oreochromis niloticus*). *Songklanakarin Journal of*
482 *Science and Technology*, 27, 307-319. Retrieved from
483 <https://sjst.psu.ac.th/article.php?art=383>


484 Suanyuk, N., Kong, F., Ko, D., Gilbert, G.L., & Supamattaya, K. (2008). Occurrence of rare
485 genotypes of *Streptococcus agalactiae* in cultured red tilapia *Oreochromis* sp. and
486 Nile tilapia *O. niloticus* in Thailand-Relationship to human isolates? *Aquaculture*,
487 284(1-4), 35-40. doi: 10.1016/j.aquaculture.2008.07.034.

- 488 Suwannasang, A., Dangwetngam, M., Issaro, A., Phromkunthong, W., & Suanyuk, N.
489 (2014). Pathological manifestations and immune responses of serotypes Ia and III
490 *Streptococcus agalactiae* infections in Nile tilapia (*Oreochromis niloticus*).
491 *Songklanakarinn Journal of Science and Technology*, 36(5), 499-506. Retrieved from
492 <https://sjst.psu.ac.th/article.php?art=1438>
- 493 Wu, Z., Zhang, Q., Lin, Y., Hao, J., Wang, S., Zhang, J., & Li, A. (2021). Taxonomic and
494 functional characteristics of the gill and gastrointestinal microbiota and its
495 correlation with intestinal metabolites in NEW GIFT strain of farmed adult Nile
496 tilapia (*Oreochromis niloticus*). *Microorganisms*, 9(3), 617. doi:
497 [10.3390/microorganisms9030617](https://doi.org/10.3390/microorganisms9030617).
- 498 Ye, X., Li, J., Lu, M., Deng, G., Jiang, X., Tian, Y., Quan, Y., & Jian, Q. (2011).
499 Identification and molecular typing of *Streptococcus agalactiae* isolated from pond-
500 cultured tilapia in China. *Fisheries Science*, 77, 623–632. doi: 10.1007/s12562-011-
501 0365-4.
- 502 Yi, H., Chang, Y.H., Oh, H.W., Bae, K.S., & Chun, J. (2003). *Zooshikella ganhwensis* gen.
503 nov., sp. nov., isolated from tidal flat sediments. *International Journal of Systematic
504 and Evolutionary Microbiology*, 53(4), 1013-1018. doi: 10.1099/ijs.0.02521-0.
- 505 Zamri-Saad, M., Amal, M.N.A., Siti-Zahrah, A., & Zulkafli, A.R. (2014). Control and
506 prevention of streptococcosis in cultured tilapia in Malaysia: a review. *Pertanika
507 Journal of Tropical Agricultural Science*, 37(4), 389-410.

508

509

510



512

513

514

515

516

517

518 **Figure 1** Phagocytic activity (a), phagocytic index (b) and average bead ingested per cell (c)


519 of Nile tilapia fed with dietary supplementation at different levels of *Z. marina*

520 cells (ZC) or *Z. marina* extracts (ZE) for 2 weeks. Values with different letters are

521 significantly different (p<0.05).

522

523
524




525
526

527 **Figure 2** Phagocytic activity (a), phagocytic index (b) and average bead ingested per cell (c) of
528 Nile tilapia fed with dietary supplementation at different levels of *Z. marina* cells (ZC)
529 or *Z. marina* extracts (ZE) for 4 weeks. Values with different letters are significantly
530 different (p < 0.05).

531

532



533


534

535 **Figure 3** Cumulative mortality of Nile tilapia fed with dietary supplementation at different
536 levels of *Z. marina* cells (ZC) or *Z. marina* extracts (ZE) for 2 weeks before
537 experimental challenge with exposure to *S. agalactiae*. Values with different
538 letters are significantly different ($p < 0.05$).

539

540

541



542

543

544 **Figure 4** Cumulative mortality of Nile tilapia fed with dietary supplementation at different
545 levels of *Z. marina* cells (ZC) or *Z. marina* extracts (ZE) for 4 weeks before
546 experimental challenge with exposure to *S. agalactiae*. Values with different
547 letters are significantly different ($p < 0.05$).

548

549 **Table 1** Compositions and proximate analyses of the experimental diets.

Ingredients	Experimental diets (g/kg)
Fish meal	300
Soybean de-hulled	300
Wheat flour	292
Fish oil	20
Soybean oil	20
Alpha-starch	50
Vitamin&Mineral mixture¹	1.5
Inositol	0.5
Choline chloride	1
Di-calcium phosphate	15
<i>Chemical composition (%)²</i>	
Protein	35.99±0.13
Lipid	8.51±0.24
Ash	9.65±0.12
Moisture	6.68±0.12

550 ¹Vitamin & Mineral premix deliver the following in unit/kg diet: Retinal (A) 8,000 IU; Cholecalciferol (D3)
 551 1,500 IU; Tocopherol (E) 100 mg; Menadione sodium bisulfite (K3) 5 mg; Thiamine (B1) 10 mg; Riboflavin
 552 (B2) 15 mg; Pyridoxine (B6) 15 mg; Cobalamin (B12) 0.02 mg; Niacin 80 mg; Calcium pantothenate 40 mg;
 553 Ascorbic acid (C) 150 mg; Biotin 0.5 mg; Folic acid 4 mg; Cu 5 mg; Fe 30 mg; Zn 40 mg; Mn 25 mg; Co 0.05
 554 mg; I 1 mg; Se 0.25 mg.

555 ²Chemical composition are expressed as means ± SD of triplicates.

Table 2 Growth performance of Nile tilapia receiving dietary supplementation with different levels557 of *Z. marina* cells or extracts.

Treatment	Initial weight (g/fish)	Final weight (g/fish)	Weight gain (%)	Specific growth rate (%)	Feed conversion ratio	Survival rate (%)
2 weeks post feeding						
T1: Control	19.01±0.16 ^{ns}	23.87±0.52 ^a	34.61±1.46 ^a	0.86±0.01 ^a	1.49±0.64 ^b	100±0.00 ^{ns}
T2: 0.5 g/kg ZC	18.84±0.01 ^{ns}	23.89±0.55 ^a	38.18±1.60 ^{ab}	0.98±0.05 ^b	1.32±0.55 ^a	100±0.00 ^{ns}
T3: 1.0 g/kg ZC	18.80±0.03 ^{ns}	24.46±0.89 ^{ab}	37.78±1.61 ^{ab}	1.02±0.10 ^b	1.30±0.45 ^a	100±0.00 ^{ns}
T4: 1.5 g/kg ZC	18.82±0.04 ^{ns}	24.69±0.64 ^b	39.90±2.84 ^b	1.04±0.11 ^b	1.28±0.46 ^a	100±0.00 ^{ns}
T5: 2.5 mg/kg ZE	18.89±0.03 ^{ns}	24.22±0.97 ^{ab}	38.39±2.89 ^{ab}	1.03±0.04 ^b	1.33±0.49 ^a	100±0.00 ^{ns}
T6: 5.0 mg/kg ZE	18.84±0.02 ^{ns}	24.48±0.58 ^{ab}	39.04±1.92 ^{ab}	1.04±0.05 ^b	1.30±0.54 ^a	100±0.00 ^{ns}
T7: 7.5 mg/kg ZE	18.93±0.13 ^{ns}	24.72±0.44 ^b	40.26±3.01 ^b	1.06±0.06 ^b	1.25±0.50 ^a	100±0.00 ^{ns}
4 weeks post feeding						
T1: Control	19.01±0.16 ^{ns}	26.78±0.42 ^a	45.17±1.97 ^a	1.26±0.11 ^a	1.62±0.46 ^b	100±0.00 ^{ns}
T2: 0.5 g/kg ZC	18.84±0.01 ^{ns}	28.96±0.13 ^{bc}	52.89±3.32 ^b	1.55±0.03 ^b	1.45±0.45 ^a	100±0.00 ^{ns}
T3: 1.0 g/kg ZC	18.80±0.03 ^{ns}	29.08±0.56 ^{bc}	55.55±3.87 ^b	1.58±0.08 ^b	1.45±0.43 ^a	100±0.00 ^{ns}
T4: 1.5 g/kg ZC	18.82±0.04 ^{ns}	29.78±0.41 ^c	58.24±3.25 ^b	1.68±0.08 ^b	1.40±0.41 ^a	100±0.00 ^{ns}
T5: 2.5 mg/kg ZE	18.89±0.03 ^{ns}	28.35±0.55 ^b	52.90±4.46 ^b	1.51±0.09 ^b	1.49±0.44 ^a	100±0.00 ^{ns}
T6: 5.0 mg/kg ZE	18.84±0.02 ^{ns}	29.24±0.19 ^{bc}	55.00±3.33 ^b	1.57±0.06 ^b	1.46±0.42 ^a	100±0.00 ^{ns}
T7: 7.5 mg/kg ZE	18.93±0.13 ^{ns}	29.86±0.18 ^c	56.25±4.92 ^b	1.65±0.06 ^b	1.43±0.50 ^a	100±0.00 ^{ns}

558 ZC= *Z. marina* cells; ZE= *Z. marina* extracts

559 Values within the same column with different superscripts are significantly different

560 (p<0.05).

Table 3 Haemato-immunological parameters of Nile tilapia fed with dietary supplementation at different levels of *Z. marina* cells or extract for 2 weeks.

Treatment	RBC (x10 ⁹ cell/mL)	WBC (x10 ⁷ cell/mL)	Haemoglobin (g/dL)	Haematocrit (%)	NBT reduction (OD ₆₃₀)	Serum protein (mg/mL)	Immunoglobulin (mg/mL)	Lysozyme (µg/mL)
T1: Control-1	2.18±0.35 ^a	6.72±1.21 ^a	3.93±0.33 ^a	24.47±1.97 ^a	1.23±0.22 ^a	24.31±2.54 ^a	0.98±0.21 ^{ns}	5.12±0.44 ^{ns}
T2: Control-2	2.22±0.32 ^a	6.35±0.90 ^a	3.46±0.95 ^a	24.25±2.74 ^a	1.17±0.21 ^a	25.28±3.35 ^a	0.96±0.63 ^{ns}	4.80±1.00 ^{ns}
T3: 0.5 g/kg ZC	2.37±0.21 ^{ab}	7.77±0.66 ^{ab}	4.14±1.26 ^a	26.74±5.22 ^{ab}	1.39±0.19 ^{ab}	27.23±2.41 ^{ab}	1.73±1.04 ^{ns}	5.25±1.25 ^{ns}
T4: 1.0 g/kg ZC	2.39±0.17 ^{ab}	7.81±0.69 ^{ab}	5.44±0.75 ^b	27.32±2.80 ^{ab}	1.41±0.22 ^{ab}	28.43±3.79 ^{ab}	1.84±1.48 ^{ns}	5.25±0.19 ^{ns}
T5: 1.5 g/kg ZC	2.56±0.29 ^b	8.47±2.04 ^b	5.83±0.87 ^b	29.50±4.76 ^b	1.73±0.58 ^b	28.71±1.30 ^{ab}	1.89±0.54 ^{ns}	6.05±0.85 ^{ns}
T6: 2.5 mg/kg ZE	2.30±0.24 ^{ab}	6.81±1.57 ^{ab}	5.05±0.83 ^b	27.94±3.34 ^{ab}	1.39±0.21 ^{ab}	27.43±1.18 ^{ab}	1.60±1.53 ^{ns}	5.32±2.05 ^{ns}
T7: 5.0 mg/kg ZE	2.42±0.15 ^{ab}	6.86±1.42 ^{ab}	5.58±0.64 ^b	28.42±2.20 ^b	1.44±0.30 ^{ab}	27.49±2.37 ^{ab}	1.76±1.68 ^{ns}	5.80±0.73 ^{ns}
T8: 7.5 mg/kg ZE	2.41±0.19 ^{ab}	6.94±1.15 ^{ab}	5.72±0.43 ^b	29.25±3.65 ^b	1.55±0.34 ^{ab}	30.30±4.70 ^b	2.71±0.80 ^{ns}	6.53±2.70 ^{ns}

ZC=*Z. marina* cells; ZE=*Z. marina* extracts; RBC=Red blood cell; WBC=White blood cell

Values within the same column with different superscripts are significantly different (p<0.05).

561 **Table 4** Haemato-immunological parameters of Nile tilapia fed with dietary supplementation at different levels of *Z. marina* cells or
 562 extract for 4 weeks.

Treatment	RBC (x10 ⁹ cell/mL)	WBC (x10 ⁷ cell/mL)	Haemoglobin (g/dL)	Haematocrit (%)	NBT reduction (OD ₆₃₀)	Serum protein (mg/mL)	Immunoglobulin (mg/mL)	Lysozyme (µg/mL)
T1: Control-1	2.40±0.08 ^a	6.62±1.34 ^a	5.80±0.41 ^a	28.03±0.37 ^a	1.05±0.19 ^{ns}	26.48±1.53 ^a	3.16±3.46 ^{ns}	6.80±0.53 ^{ns}
T2: Control-2	2.34±0.12 ^a	6.66±0.74 ^a	5.75±0.74 ^a	27.98±0.38 ^a	1.06±0.34 ^{ns}	26.20±1.50 ^a	2.97±2.68 ^{ns}	5.60±0.93 ^{ns}
T3: 0.5 g/kg ZC	2.38±0.13 ^a	6.65±1.26 ^a	6.56±0.91 ^{ab}	29.50±2.97 ^{ab}	1.13±0.39 ^{ns}	29.76±4.15 ^{ab}	3.19±2.35 ^{ns}	5.80±2.31 ^{ns}
T4: 1.0 g/kg ZC	2.49±0.31 ^{ab}	7.63±0.72 ^{ab}	6.58±0.78 ^{ab}	30.11±4.82 ^{ab}	1.13±0.45 ^{ns}	29.97±1.91 ^{ab}	4.73±2.71 ^{ns}	6.60±2.14 ^{ns}
T5: 1.5 g/kg ZC	2.58±0.31 ^{ab}	7.82±1.13 ^b	6.94±1.01 ^b	32.33±4.20 ^b	1.35±0.46 ^{ns}	31.72±4.38 ^b	5.25±2.73 ^{ns}	7.47±1.21 ^{ns}
T6: 2.5 mg/kg ZE	2.52±0.22 ^{ab}	6.63±0.71 ^a	6.67±1.10 ^{ab}	29.93±1.98 ^{ab}	1.15±0.21 ^{ns}	30.34±4.83 ^{ab}	5.17±0.99 ^{ns}	6.57±1.65 ^{ns}
T7: 5.0 mg/kg ZE	2.56±0.15 ^b	6.72±0.55 ^a	6.70±0.58 ^{ab}	32.44±2.77 ^b	1.16±0.09 ^{ns}	30.79±2.35 ^{ab}	5.24±2.72 ^{ns}	6.93±0.90 ^{ns}
T8: 7.5 mg/kg ZE	2.66±0.08 ^b	7.70±0.89 ^{ab}	6.80±0.66 ^{ab}	32.93±3.48 ^b	1.20±0.13 ^{ns}	31.51±2.68 ^b	6.00±2.77 ^{ns}	6.94±1.30 ^{ns}

563 ZC=*Z. marina* cells; ZE=*Z. marina* extracts; RBC=Red blood cell; WBC=White blood cell

564 Values within the same column with different superscripts are significantly different (p<0.05).